{"id":15675,"date":"2022-01-19T20:52:44","date_gmt":"2022-01-19T19:52:44","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15675"},"modified":"2022-01-19T20:52:44","modified_gmt":"2022-01-19T19:52:44","slug":"enasidenib-aza-la-combinaison-gagnante-pour-les-lam-idh-2-mutees","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/enasidenib-aza-la-combinaison-gagnante-pour-les-lam-idh-2-mutees\/","title":{"rendered":"Enasid\u00e9nib + AZA : la combinaison gagnante pour les LAM IDH 2 mut\u00e9es !"},"content":{"rendered":"<p>R\u00e9f :HematoStat.net ; 1 (12) : V33<\/p>\n<p><a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(21)00494-0\/fulltext\"><em>Courtney D DiNardo and al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 tril.. The Lancet Oncology. Vol22, Issue11, p1597-1608<\/em>. Doi : 10.1016\/S1470-2045(21)00494-0<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>R\u00e9f :HematoStat.net ; 1 (12) : V33 Courtney D DiNardo and al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, [&hellip;]<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[11],"tags":[227,228,61],"ppma_author":[442],"class_list":["post-15675","post","type-post","status-publish","format-standard","hentry","category-veille-bibliographique","tag-azacytidine","tag-enasidenib","tag-lam","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15675"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15675\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15675"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}